Point: Major adverse cardiovascular events and anti-IL 12/23 agents.
Department of Pharmacology and Clinical Pharmacology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany.
Thrasivoulos
T
Tzellos
Department of Pharmacology and Clinical Pharmacology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany.
Athanassios
A
Kyrgidis
Hospital for Skin and Venereal Diseases, Thessaloniki, Greece.
Anastasia
A
Trigoni
Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany. Electronic address: christos.zouboulis@klinikum-dessau.de.
Christos C
CC
Zouboulis
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized